Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;202(1):5-16.
doi: 10.1007/s00408-023-00666-y. Epub 2023 Dec 21.

The Therapeutic Landscape in Chronic Cough

Jaclyn A Smith  1   2
Affiliations
Review

The Therapeutic Landscape in Chronic Cough

Jaclyn A Smith. Lung. 2024 Feb.

Abstract

In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.

Keywords: Antitussives; Idiopathic pulmonary fibrosis; P2X3 antagonists; Refractory chronic cough.

PubMed Disclaimer

Conflict of interest statement

JAS has received consultancy fees from Axalbion, Algernon, AstraZeneca, Bayer, Bellus Health, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Nocion Therapeutics, Shionogi, and Trevi Therapeutics. The VitaloJAK algorithm has been licenced by Manchester University Foundation Trust (MFT) and the University of Manchester to Vitalograph Ltd and Vitalograph Ireland. MFT receives royalties which may be shared with the clinical division in which JAS works.

Figures

Fig. 1
Fig. 1
Clinical pathways of patients requiring cough treatments; COPD chronic obstructive pulmonary disease, IPF idiopathic pulmonary fibrosis
Fig. 2
Fig. 2
Mechanisms of action of antitussive therapies
Fig. 3
Fig. 3
Current antitussive pipeline 2023. RCC refractory chronic cough, IPF idiopathic pulmonary fibrosis, NaV voltage-gated sodium channel, TRPM8 transient receptor vanilloid potential melastatin 8, OR opioid receptor, NK-1 neurokinin-1, NMDA N-methyl-d-aspartate
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Song WJ, Chang YS, Faruqi S, Kim JY, Kang MG, Kim S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479–81. - PubMed
    1. Colak Y, Nordestgaard BG, Laursen LC, Afzal S, Lange P, Dahl M. Risk factors for chronic cough among 14,669 individuals from the general population. Chest. 2017;152(3):563–73. - PubMed
    1. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020 doi: 10.1183/13993003.01136-2019. - DOI - PMC - PubMed
    1. Saunders P, Wu Z, Fahy WA, Stewart ID, Saini G, Smith DJF, et al. The burden and impact of cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study. Ann Am Thorac Soc. 2023;20(9):1267–73. - PMC - PubMed
    1. Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6:4. - PMC - PubMed

Publication types

Substances